"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2008/0213892 A1,057-663-372-019-147,2008-09-04,2008,US 4153808 A,2008-03-03,US 4153808 A;;US 90459607 P,2007-03-02,SELF-RENEWAL OF NEURAL STEM CELLS IS PROMOTED BY WNT PROTEINS,Mammalian neural progenitor or stem cells are expanded in vitro by culture in the presence of one or more wnt polypeptides. The expanded cells substantially maintain their original phenotype including the ability to give rise to multiple types of differentiated cells.,UNIV LELAND STANFORD JUNIOR,NUSSE ROELAND;;KALANI M YASHAR S;;CHESHIER SAMUEL,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2008-04-11),https://lens.org/057-663-372-019-147,Patent Application,yes,14,9,1,1,0,C12N5/0623;;C12N5/0623;;C12N2501/11;;C12N2501/11;;C12N2501/115;;C12N2501/115;;C12N2501/13;;C12N2501/13;;C12N2501/415;;C12N2501/415,C12N5/0797,435/377,0,0,,,,DISCONTINUED
2,CA,A1,CA 3055957 A1,180-351-174-116-735,2018-09-13,2018,CA 3055957 A,2018-03-05,US 201762469378 P;;US 2018/0020905 W,2017-03-09,TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING OF CD47 PATHWAY,Methods are provided for targeting pediatric brain tumor cells for depletion.,UNIV LELAND STANFORD JUNIOR,GHOLAMIN SHARAREH;;CHESHIER SAMUEL;;MITRA SIDDHARTHA S;;WEISSMAN IRVING L,,https://lens.org/180-351-174-116-735,Patent Application,no,0,0,6,6,0,C07K2317/52;;C07K2317/73;;C07K2317/76;;C07K16/2803;;A61P35/00;;A61K2039/505;;C07K2317/24;;A61K9/0004;;C07K16/2803;;A61P35/00;;A61K2039/505;;C07K2317/24;;A61K9/0004;;C07K2317/52;;C07K2317/76;;C07K2317/73,A61K39/395,,0,0,,,,PENDING
3,EP,A1,EP 3592387 A1,086-164-066-751-394,2020-01-15,2020,EP 18764940 A,2018-03-05,US 201762469378 P;;US 2018/0020905 W,2017-03-09,TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING OF CD47 PATHWAY,,UNIV LELAND STANFORD JUNIOR,GHOLAMIN SHARAREH;;CHESHIER SAMUEL;;MITRA SIDDHARTHA S;;WEISSMAN IRVING L,,https://lens.org/086-164-066-751-394,Patent Application,yes,0,0,6,6,0,A61K9/0004;;A61K9/0004;;A61K2039/505;;A61K2039/505;;A61P35/00;;A61P35/00;;C07K16/2803;;C07K16/2803;;C07K2317/24;;C07K2317/24;;C07K2317/52;;C07K2317/52;;C07K2317/73;;C07K2317/73;;C07K2317/76;;C07K2317/76,A61K39/395,,0,0,,,,PENDING
4,EP,A4,EP 3592387 A4,130-929-736-702-117,2021-03-31,2021,EP 18764940 A,2018-03-05,US 201762469378 P;;US 2018/0020905 W,2017-03-09,TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING OF CD47 PATHWAY,,UNIV LELAND STANFORD JUNIOR,GHOLAMIN SHARAREH;;CHESHIER SAMUEL;;MITRA SIDDHARTHA S;;WEISSMAN IRVING L,,https://lens.org/130-929-736-702-117,Search Report,no,0,0,6,6,0,A61K9/0004;;A61K9/0004;;A61K2039/505;;A61K2039/505;;A61P35/00;;A61P35/00;;C07K16/2803;;C07K16/2803;;C07K2317/24;;C07K2317/24;;C07K2317/52;;C07K2317/52;;C07K2317/73;;C07K2317/73;;C07K2317/76;;C07K2317/76,C07K16/28;;A61K39/395;;A61P35/00,,9,6,067-661-409-599-434;;043-106-949-782-922;;011-097-564-605-594;;046-484-844-733-099;;048-467-255-045-448;;136-563-202-750-151,23575267;;10.4161/mabs.22970;;pmc3893230;;28076333;;pmc5355332;;10.18632/oncotarget.14553;;pmc4836698;;10.1371/journal.pone.0153550;;27092773;;10.1371/journal.pone.0137345;;pmc4577081;;26390038;;10.3791/50326;;pmc3679837;;23712122;;10.1126/scitranslmed.aaf2968;;28298418,"SHARAREH GHOLAMIN ET AL: ""Abstract 5218: Development of Anti-CD47 therapy for pediatric brain tumors. | Cancer Research"", AACR PUBLICATIONS, 1 April 2013 (2013-04-01), XP055746121, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/73/8_Supplement/5218> [retrieved on 20201102];;CABANAS RICARDO ET AL: ""Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience"", MABS, vol. 5, no. 2, March 2013 (2013-03-01), pages 202 - 207, XP002800909, ISSN: 1942-0862;;LENKOV, O. ET AL.: ""Nanoparticle-based translational MR Imaging for immune-therapy trials in glioblastoma"", MOLECULAR IMAGING & BIOLOGY, ELSEVIER, BOSTON, vol. 18, no. Suppl 1, 23 May 2016 (2016-05-23), pages 1 - 1553, XP037068321, ISSN: 1536-1632, [retrieved on 20160523], DOI: 10.1007/S11307-016-0969-2;;ZHU HUAIYANG ET AL: ""Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy"", vol. 8, no. 7, 14 February 2017 (2017-02-14), pages 12145 - 12157, XP009523856, ISSN: 1949-2553, Retrieved from the Internet <URL:https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.14553> [retrieved on 20170105], DOI: 10.18632/ONCOTARGET.14553;;MICHAEL ZHANG ET AL: ""Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo"", PLOS ONE, vol. 11, no. 4, 19 April 2016 (2016-04-19), pages 1 - 21, XP055559968, DOI: 10.1371/journal.pone.0153550;;JIE LIU ET AL: ""Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential"", PLOS ONE, vol. 10, no. 9, 21 September 2015 (2015-09-21), pages 1 - 23, XP055223677, DOI: 10.1371/journal.pone.0137345;;SARAH L. DEVOS ET AL: ""Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System"", JOURNAL OF VISUALIZED EXPERIMENTS, vol. 75, 12 May 2013 (2013-05-12), pages 1 - 10, XP055559988, DOI: 10.3791/50326;;SHARAREH GHOLAMIN ET AL: ""Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors"", 15 March 2017 (2017-03-15), XP055745619, Retrieved from the Internet <URL:http://stm.sciencemag.org> [retrieved on 20201030];;See also references of WO 2018165015A1",PENDING
5,US,A1,US 2018/0258170 A1,149-787-150-842-787,2018-09-13,2018,US 201815912447 A,2018-03-05,US 201815912447 A;;US 201762469378 P,2017-03-09,TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING OF CD47 PATHWAY,Methods are provided for targeting pediatric brain tumor cells for depletion.,UNIV LELAND STANFORD JUNIOR,GHOLAMIN SHARAREH;;CHESHIER SAMUEL;;MITRA SIDDHARTHA S;;WEISSMAN IRVING L,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2018-04-03),https://lens.org/149-787-150-842-787,Patent Application,yes,0,1,6,6,0,A61K9/0004;;A61K9/0004;;A61K2039/505;;A61K2039/505;;A61P35/00;;A61P35/00;;C07K16/2803;;C07K16/2803;;C07K2317/24;;C07K2317/24;;C07K2317/52;;C07K2317/52;;C07K2317/73;;C07K2317/73;;C07K2317/76;;C07K2317/76,C07K16/28;;A61K9/00;;A61P35/00,,0,0,,,,ACTIVE
6,WO,A1,WO 2018/165015 A1,161-928-616-716-987,2018-09-13,2018,US 2018/0020905 W,2018-03-05,US 201762469378 P,2017-03-09,TREATMENT OF PEDIATRIC BRAIN TUMORS WITH TARGETING OF CD47 PATHWAY,Methods are provided for targeting pediatric brain tumor cells for depletion.,UNIV LELAND STANFORD JUNIOR,GHOLAMIN SHARAREH;;CHESHIER SAMUEL;;MITRA SIDDHARTHA S;;WEISSMAN IRVING L,,https://lens.org/161-928-616-716-987,Patent Application,yes,25,2,6,6,0,A61K9/0004;;A61K9/0004;;A61K2039/505;;A61K2039/505;;A61P35/00;;A61P35/00;;C07K16/2803;;C07K16/2803;;C07K2317/24;;C07K2317/24;;C07K2317/52;;C07K2317/52;;C07K2317/73;;C07K2317/73;;C07K2317/76;;C07K2317/76,A61K39/395,,26,13,011-097-564-605-594;;048-467-255-045-448;;067-661-409-599-434;;043-106-949-782-922;;044-083-264-821-21X;;095-735-199-144-152;;000-061-506-530-48X;;081-155-726-262-080;;089-039-059-182-177;;033-401-440-963-789;;091-377-426-321-911;;045-149-256-448-908;;138-344-087-704-67X,pmc4836698;;10.1371/journal.pone.0153550;;27092773;;10.3791/50326;;pmc3679837;;23712122;;23575267;;10.4161/mabs.22970;;pmc3893230;;28076333;;pmc5355332;;10.18632/oncotarget.14553;;10.4049/jimmunol.179.11.7741;;18025220;;10.1016/j.molcel.2008.05.026;;18657508;;10.1074/jbc.m611511200;;17369261;;10.1074/jbc.m110.180018;;20826801;;pmc2992229;;10.1158/0008-5472.can-03-1708;;14871834;;8417368;;10.1016/0161-5890(93)90432-b;;10.1038/371346a0;;8090205;;2218494;;10.1126/science.2218494;;10.1016/s0169-409x(97)00053-7;;10837567,"ZHANG ET AL.: ""Anti- CD 47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo"", PLOS ONE, vol. 11, 19 April 2016 (2016-04-19), pages 1 - 21, XP055559968;;DEVOS ET AL.: ""Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System"", JOURNAL OF VISUALIZED EXPERIMENTS, vol. 75, 12 May 2013 (2013-05-12), pages 1 - 10, XP055559988;;See also references of EP 3592387A4;;GHOLAMIN ET AL., PROCEEDINGS: AACR 104TH ANNUAL MEETING, 2013;;CABANAS ET AL., MABS, vol. 5, no. 2, 2013, pages 202 - 207;;LENKOV ET AL., MOLECULAR IMAGING & BIOLOGY, vol. 18, no. S1, 2016, pages 2234141;;ZHU ET AL., ONCOTARGET, vol. 8, no. 7, 2017, pages 12145 - 12157;;ZHANG ET AL., PLOS ONE, vol. 11, no. 4, 2016, pages 1 - 21;;LIU ET AL., PLOS ONE, vol. 10, no. 9, 2015, pages 1 - 23;;DEVOS ET AL., JOURNAL OF VISUALIZED EXPERIMENTS, vol. 75, 2013, pages 1 - 10;;MANIATISFRITSCHSAMBROOK, MOLECULAR CLONING: A LABORATORY MANUAL, 1982;;SAMBROOKRUSSELLSAMBROOK, MOLECULAR CLONING: A LABORATORY MANUAL, 2001;;HARLOWLANEHARLOW: ""Using Antibodies: A Laboratory Manual: Portable Protocol"", 1998, COLD SPRING HARBOR LABORATORY;;HARLOWLANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;LEE ET AL., J. IMMUNOL., vol. 179, 2007, pages 7741 - 7750;;HATHERLEY ET AL., MOL CELL, vol. 31, no. 2, 2008, pages 266 - 77;;HATHERLEY ET AL., J.B.C., vol. 282, 2007, pages 14567 - 75;;LEE, J.B.C., vol. 285, 2010, pages 37953 - 63;;MANNAFRAZIER, CANCER RESEARCH, vol. 64, 1 February 2004 (2004-02-01), pages 1026 - 1036;;ANGAL ET AL., MOL. IMMUNOL., vol. 30, no. 1, 1993, pages 105 - 108;;LAZEBNIK ET AL., NATURE, vol. 371, 1994, pages 346;;LANGER, SCIENCE, vol. 249, 1990, pages 1527;;HANES, ADVANCED DRUG DELIVERY REVIEWS, vol. 28, 1997, pages 97 - 119;;""Remington's Pharmaceutical Science"", 1980;;GOODMANGILLMAN ET AL.: ""The Pharmacological Basis of Therapeutics"", 1996;;MONJEFISHER, J PEDIATR REHABIL MED, vol. 4, 2011, pages 31 - 36",PENDING
7,US,B2,US 11078272 B2,116-251-955-498-626,2021-08-03,2021,US 201815912447 A,2018-03-05,US 201815912447 A;;US 201762469378 P,2017-03-09,Treatment of pediatric brain tumors with targeting of CD47 pathway,Methods are provided for targeting pediatric brain tumor cells for depletion.,UNIV LELAND STANFORD JUNIOR,GHOLAMIN SHARAREH;;CHESHIER SAMUEL;;MITRA SIDDHARTHA S;;WEISSMAN IRVING L,THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (2018-04-03),https://lens.org/116-251-955-498-626,Granted Patent,yes,27,0,6,6,0,A61K9/0004;;A61K9/0004;;A61K2039/505;;A61K2039/505;;A61P35/00;;A61P35/00;;C07K16/2803;;C07K16/2803;;C07K2317/24;;C07K2317/24;;C07K2317/52;;C07K2317/52;;C07K2317/73;;C07K2317/73;;C07K2317/76;;C07K2317/76,C07K16/28;;A61K9/00;;A61K39/00;;A61P35/00,,12,9,021-815-766-516-14X;;048-467-255-045-448;;011-097-564-605-594;;067-661-409-599-434;;048-467-255-045-448;;136-563-202-750-151;;046-484-844-733-099;;011-097-564-605-594;;043-106-949-782-922,10.1093/neuonc/nov217.25;;10.3791/50326;;pmc3679837;;23712122;;pmc4836698;;10.1371/journal.pone.0153550;;27092773;;23575267;;10.4161/mabs.22970;;pmc3893230;;10.3791/50326;;pmc3679837;;23712122;;10.1126/scitranslmed.aaf2968;;28298418;;10.1371/journal.pone.0137345;;pmc4577081;;26390038;;pmc4836698;;10.1371/journal.pone.0153550;;27092773;;28076333;;pmc5355332;;10.18632/oncotarget.14553,"Gholamin et al (Molecular and Cellular Biology, 2013, 73(8): Abstract 5218).;;Gholamin et al (Neuro-Oncology, 2015, 17(Suppl 5): v118: IMPS-26).;;DeVos et al., “Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System”, Journal of Visualized Experiments, May 12, 2013, pp. 1-10, (75), e50326, Creative Commons Attribution, Mountain View, CA.;;Zhang et al., “Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo”, Plos One, Apr. 19, 2016, pp. l-21, Plos, San Francisco, CA.;;Cabanas et al. (2013) “Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience” MABS, vol. 5. No. 2, pp. 202-207.;;DeVos et al. (2013) “Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System”, Journal of Visualized Experiments, vol. 75. pp. 1-10.;;Gholamin et al. (2013) “Abstract 5218 Development of Anti-CD47 therapy for pediatric brain tumors”, Cancer Research, AACR Publications, Abstract 5218, XP55746121.;;Gholamin et al. (2017) “Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors” pgs, XP55745619.;;Liu et al. (2015) “Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential”. Plos One. vo 1 • 10. No. 9, pp. 1-23.;;Lenkov et al. (2016) “Nanoparticle-based translational MR Imaging for immune-therapy trials in glioblastoma”, Molecular Imaging & Biology Elsevier Boston, vol. 18. No., pp. 1-1553.;;Zhang et al: “Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo”. Plos One. vol. 11. No. 4. pp. 1-21.;;Zhu et al. (2017) “Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapyn” Oncotarget. Impact Journals LLC. United Statesvo 1. 8. No. 7, pp. 12145-12157.",ACTIVE
